Carcinoma, Basal Cell clinical trials

The registry lists 389 studies for Carcinoma, Basal Cell across more than 10 countries. 69 are recruiting or about to start. 286 of them are mainly about Carcinoma, Basal Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its narrower condition Basal Cell Nevus Syndrome too: 401 studies, 72 open.

Get an email when these change. Save the Carcinoma, Basal Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 210
Recruiting: 52
Status unknown: 43
Active, not recruiting: 27
Terminated: 24
Not yet recruiting: 14

Phase

Phase 2: 104
Phase 1: 59
Phase 3: 30
Early Phase 1: 11
Phase 4: 10

Where

United States: 171
France: 33
Germany: 31
United Kingdom: 29
Netherlands: 25
Denmark: 21

Who runs them

Maastricht University Medical Center (18) · National Cancer Institute (NCI) (9) · Bispebjerg Hospital (8) · Novartis Pharmaceuticals (8) · Hoffmann-La Roche (7) · Memorial Sloan Kettering Cancer Center (7) · Galderma R&D (6) · Genentech, Inc. (6)

What is being tested here

Drugs under test in Carcinoma, Basal Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Nivolumab	4	0	8
Daromun	3	0	3
Cemiplimab	2	0	6
Ipilimumab	2	0	4
Niacinamide	2	1	3
Darleukin	2	0	2
Onfekafusp alfa	2	0	2
Relatlimab	2	0	2
HhAntag691	1	0	19
Imiquimod	1	5	12

Drug classes tested here Immune checkpoint inhibitors 6 open · Antimetabolites 1 open · NSAIDs 3

Coming up

7phase 3 studies under way

33studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Aug 2027Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial · Phase 3 · Women's College Hospital
Nov 2026Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome · Centre Hospitalier Universitaire de Nīmes
Dec 2026Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) · Highlight Therapeutics
Dec 2026Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers · University of Wisconsin, Madison
Dec 2026Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT) · Alpha Tau Medical LTD.
Dec 2026Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas · Nathalie Zeitouni
Dec 2026Intraoperative Confocal Laser Scanning Microscopy With Use of AI for Optimized Surgical Excision of Basal Cell Carcinoma · LMU Klinikum
Jan 2027Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors · Alpha Tau Medical LTD.
Jan 2027Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia · Alpha Tau Medical LTD.
Jan 2027In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors · University of Southern California

Who these studies take

Of the 52 Carcinoma, Basal Cell studies recruiting now, 48 (92%) set no upper age limit and 0 (0%) stop at 75 or younger. 9 (17%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (4%) take healthy volunteers.

Recruiting studies that take each age, of 52
Age	Women	Men
10	9 (17%)	9 (17%)
18	51 (98%)	51 (98%)
30	51 (98%)	51 (98%)
40	51 (98%)	51 (98%)
50	51 (98%)	51 (98%)
65	52 (100%)	52 (100%)
75	52 (100%)	52 (100%)
85	52 (100%)	52 (100%)

Across all 389 studies, recruiting or not: 5% stop at 75 or younger and 2% at 65; 10% take children; 1% are for women only and 0% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Carcinoma, Basal Cell studies take

Of 43 phase 2 interventional studies under Carcinoma, Basal Cell, half reached primary completion within 46 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	40 mo19–51 · 28 studies	—	—
Phase 2	46 mo24–67 · 43 studies	—	—
Interventional, no phase	31 mo22–64 · 50 studies	—	—
Observational	50 mo24–75 · 40 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 389. Browse all 389 → or search them.